Log in

ID1 Identifai Genetics Limited ASX · Australia

Identifai Genetics (ID1) news

Identifai Genetics Limited is a public biotech or pharmaceutical company listed on ASX under the ticker ID1, recorded under Australia. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Identifai Genetics news

We have not published a story on Identifai Genetics yet. When there is news, it will appear here.

Questions about Identifai Genetics

What is the ticker symbol of Identifai Genetics?

Identifai Genetics Limited trades under the ticker ID1 on ASX.

Where is Identifai Genetics listed?

Identifai Genetics Limited is listed on ASX.

Which country or territory is Identifai Genetics listed under?

Our directory records Identifai Genetics Limited under Australia.

What does Identifai Genetics do?

Our directory classifies Identifai Genetics Limited as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of Identifai Genetics?

The ISIN recorded for Identifai Genetics Limited is AU0000488983.

Does aibio.space cover Identifai Genetics?

aibio.space lists Identifai Genetics Limited among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Identifai Genetics?

Companies in our directory listed in the same country and business area as Identifai Genetics: Telix Pharmaceuticals, Polynovo, Argenica Therapeutics, Immutep, Kazia Therapeutics, Amplia Therapeutics.

Investor discussion: Identifai Genetics

Members talk about Identifai Genetics (ID1). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open ASX:ID1 on TradingView.

Listing details

Identifai Genetics Limited is a public biotech or pharmaceutical company listed on ASX under the ticker ID1, recorded under Australia. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Identifai Genetics Limited
Ticker
ID1
Listing
ASX
Country or territory
Australia
Business scope
Biotechnology
ISIN
AU0000488983
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.